← All organizations
Highest phase reached
Phase 3
First clinical trial
Mar 1, 2002First marketed drug
Nov 14, 2022First NDA
Nov 14, 2022Last known activity
Jan 13, 2024
Acquired by AbbVie on Nov 30, 2023
Timeline
1980s
- Jan 1, 1981
Immunogen— Founded
2010s
- Mar 1, 2016
Alvine Pharmaceuticals Inc.— Acquired
2020s
- Nov 14, 2022
mirvetuximab soravtansine— Marketing Organization
- Nov 14, 2022
mirvetuximab soravtansine— NDA Organization
- Nov 14, 2022
mirvetuximab soravtansine— NDA Secondary Org
- Nov 30, 2023
AbbVie— Acquired By
Drugs by trial phase (35 distinct, 41 trials)
Phase 3 (6 own, 0 via acquisition)
Phase 2 (20 own, 1 via acquisition)
Phase 1 (8 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adenocarcinoma, Clear Cell
- Carcinoma
- Carcinoma, Merkel Cell
- Carcinoma, Ovarian Epithelial
- Carcinosarcoma
- Celiac Disease
- Cystadenocarcinoma, Serous
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Mesothelioma
- Mixed Tumor, Mullerian
- Multiple Myeloma
- Myeloproliferative Disorders
- Neoplasms
- Neoplasms, Plasma Cell
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Peritoneal Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Small Cell Lung Carcinoma
- Stomach Neoplasms
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (45)
- NCT06034470CollaboratorPhase 1Jan 13, 2024
- NCT05887609CollaboratorPhase 2Oct 3, 2023
- NCT05445778Lead sponsorPhase 3Dec 31, 2022
- NCT05320380CollaboratorPhase 1/Phase 2Dec 20, 2022
- NCT05527184Lead sponsorPhase 1Dec 6, 2022
- NCT05456685Lead sponsorPhase 2Sep 28, 2022
- NCT04839575Lead sponsorPhase 2Oct 31, 2021
- NCT05041257Lead sponsorPhase 2Aug 31, 2021
- NCT04622774Study directorPhase 1Oct 26, 2020
- NCT04622774Lead sponsorPhase 1Oct 26, 2020
- NCT04296890Study directorPhase 3Apr 30, 2020
- NCT04296890Lead sponsorPhase 3Apr 30, 2020
- NCT04243551Lead sponsorPhase 2Feb 29, 2020
- NCT04209855Study directorPhase 3Dec 31, 2019
- NCT04209855Lead sponsorPhase 3Dec 31, 2019
Details
- Founded
- Waltham, MA, US Jan 1, 1981
- First NDA
- Nov 14, 2022
- Last known activity
- Jan 13, 2024
Designations held
- Orphan drug
- Fast track
- Priority review
- Accelerated approval